|
1
|
Jemal A, Siegel R, Xu J and Ward E: Cancer
statistics 2010. CA Cancer J Clin. 60:277–300. 2010. View Article : Google Scholar
|
|
2
|
Xiang YB, Zhang W, Gao LF, Liu ZW, Xu WH,
Liu EJ and Ji BT: Methods for time analysis of cancer incidence
rates. Chin J Epidemiol. 25:173–177. 2004.
|
|
3
|
Thomas ES, Gomez HL, Li RK, Chung HC, Fein
LE, Chan VF, Jassem J, Pivot XB, Klimovsky JV, de Mendoza FH, Xu B,
Campone M, Lerzo GL, Peck RA, Mukhopadhyay P, Vahdat LT and Roché
HH: Ixabepilone plus capecitabine for metastatic breast cancer
progressing after anthracycline and taxane treatment. J Clin Oncol.
25:5210–5217. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
O'Shaughnessy J, Twelves C and Aapro M:
Treatment for anthracycline-pretreated metastatic breast cancer.
Oncologist. 7(Suppl 6): 4–12. 2002.
|
|
5
|
Bonneterre J, Buzdar A, Nabholtz JM,
Robertson JF, Thürlimann B, von Euler M, Sahmoud T, Webster A and
Steinberg M; Arimidex Writing Committee; Investigators Committee
Members: Anastrozole is superior to tamoxifen as first-line therapy
in hormone receptor positive advanced breast carcinoma. Cancer.
92:2247–2258. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Mouridsen H, Gershanovich M, Sun Y,
Perez-Carrion R, Boni C, Monnier A, Apffelstaedt J, Smith R,
Sleeboom HP, Jaenicke F, Pluzanska A, Dank M, Becquart D, Bapsy PP,
Salminen E, Snyder R, Chaudri-Ross H, Lang R, Wyld P and Bhatnagar
A: Phase III study of letrozole versus tamoxifen as first-line
therapy of advanced breast cancer in postmenopausal women: analysis
of survival and update of efficacy from the International Letrozole
Breast Cancer Group. J Clin Oncol. 21:2101–2109. 2003. View Article : Google Scholar
|
|
7
|
Marty M, Cognetti F, Maraninchi D, Snyder
R, Mauriac L, Tubiana-Hulin M, Chan S, Grimes D, Antón A, Lluch A,
Kennedy J, O'Byrne K, Conte P, Green M, Ward C, Mayne K and Extra
JM: Randomized phase II trial of the efficacy and safety of
trastuzumab combined with docetaxel in patients with human
epidermal growth factor receptor 2-positive metastatic breast
cancer administered as first-line treatment: the M77001 Study
Group. J Clin Oncol. 23:4265–4274. 2005. View Article : Google Scholar
|
|
8
|
Slamon DJ, Leyland-Jones B, Shak S, Fuchs
H, Paton V, Bajamonde A, Fleming T, Eiermann W, Wolter J, Pegram M,
Baselga J and Norton L: Use of chemotherapy plus a monoclonal
antibody against HER2 for metastatic breast cancer that
overexpresses HER2. N Engl J Med. 344:783–792. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Geyer CE, Forster J, Lindquist D, Chan S,
Romieu CG, Pienkowski T, Jagiello-Gruszfeld A, Crown J, Chan A,
Kaufman B, Skarlos D, Campone M, Davidson N, Berger M, Oliva C,
Rubin SD, Stein S and Cameron D: Lapatinib plus capecitabine for
HER2-positive advanced breast cancer. N Engl J Med. 355:2733–2743.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Dawood S, Broglio K, Gonzalez-Angulo AM,
Buzdar AU, Hortobagyi GN and Giordano SH: Trends in survival over
the past two decades among white and black patients with newly
diagnosed stage IV breast cancer. J Clin Oncol. 26:4891–4898. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Press MF, Cordon-Cardo C and Slamon DJ:
Expression of the HER-2/neu proto-oncogene in normal human adult
and fetal tissues. Oncogene. 5:953–962. 1990.PubMed/NCBI
|
|
12
|
Schechter AL, Stern DF, Vaidyanathan L,
Decker SJ, Drebin JA, Greene MI and Weinberg RA: The neu oncogene:
an erb-B-related gene encoding a 185,000-Mr tumour antigen. Nature.
312:513–516. 1984. View
Article : Google Scholar : PubMed/NCBI
|
|
13
|
Zhang D, Salto-Tellez M, Do E, Putti TC
and Koay ES: Evaluation of HER-2/neu oncogene status in breast
tumors on tissue microarrays. Hum Pathol. 34:362–368. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Shimizu C, Fukutomi T, Tsuda H,
Akashi-Tanaka S, Watanabe T, Nanasawa T and Sugihara K: c-erbB-2
protein overexpression and p53 immunoreaction in primary and
recurrent breast cancer tissues. J Surg Oncol. 73:17–20. 2000.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Vogel CL and Franco SX: Clinical
experience with trastuzumab (herceptin). Breast J. 9:452–462. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Cho EY, Han JJ, Choi YL, Kim KM and Oh YL:
Comparison of Her-2, EGFR and cyclin D1 in primary breast cancer
and paired metastatic lymph nodes: an immunohistochemical and
chromogenic in situ hybridization study. J Korean Med Sci.
23:1053–1061. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Carlsson J, Nordgren H, Sjöström J, Wester
K, Villman K, Bengtsson NO, Ostenstad B, Lundqvist H and Blomqvist
C: HER2 expression in breast cancer primary tumours and
corresponding metastases. Original data and literature review. Br J
Cancer. 90:2344–2348. 2004.PubMed/NCBI
|
|
18
|
Tsutsui S, Ohno S, Murakami S, Kataoka A,
Kinoshita J and Hachitanda Y: EGFR, c-erbB2 and p53 protein in the
primary lesions and paired metastatic regional lymph nodes in
breast cancer. Eur J Surg Oncol. 28:383–387. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Gancberg D, di Leo A, Cardoso F, Rouas G,
Pedrocchi M, Paesmans M, Verhest A, Bernard-Marty C, Piccart MJ and
Larsimont D: Comparison of HER-2 status between primary breast
cancer and corresponding distant metastatic sites. Ann Oncol.
13:1036–1043. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Vincent-Salomon A, Jouve M, Genin P,
Fréneaux P, Sigal-Zafrani B, Caly M, Beuzeboc P, Pouillart P and
Sastre-Garau X: HER2 status in patients with breast carcinoma is
not modified selectively by preoperative chemotherapy and is stable
during the metastatic process. Cancer. 94:2169–2173. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Carlsson J, Forssell Aronsson E, Hietala
SO, Stigbrand T and Tennvall J: Tumour therapy with radionuclides:
assessment of progress and problems. Radiother Oncol. 66:107–117.
2003. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Wei Q, Sheng L, Shui Y, Hu Q, Nordgren H
and Carlsson J: EGFR, HER2 and HER3 expression in laryngeal primary
tumours and corresponding metastases. Ann Surg Oncol. 15:1193–1201.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Bilous M, Dowsett M, Hanna W, Isola J,
Lebeau A, Moreno A, Penault-Llorca F, Rüschoff J, Tomasic G and van
de Vijver M: Current perspectives on HER2 testing: a review of
National Testing Guidelines. Mod Pathol. 16:173–182. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Braun S, Schlimok G, Heumos I, Schaller G,
Riethdorf L, Riethmüller G and Pantel K: ErbB2 overexpression on
occult metastatic cells in bone marrow predicts poor clinical
outcome of stage I–III breast cancer patients. Cancer Res.
61:1890–1895. 2001.PubMed/NCBI
|
|
25
|
Cardoso F, di Leo A, Larsimont D, Gancberg
D, Rouas G, Dolci S, Ferreira F, Paesmans M and Piccart M:
Evaluation of HER2, p53, bcl-2, topoisomerase II-alpha, heat shock
proteins 27 and 70 in primary breast cancer and metastatic
ipsilateral axillary lymph nodes. Ann Oncol. 12:615–620. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Thompson AM, Jordan LB, Quinlan P,
Anderson E, Skene A, Dewar JA and Purdie CA; Breast Recurrence in
Tissues Study Group: Prospective comparison of switches in
biomarker status between primary and recurrent breast cancer: the
Breast Recurrence In Tissues Study (BRITS). Breast Cancer Res.
12:R922010. View
Article : Google Scholar
|
|
27
|
Tapia C, Savic S, Wagner U, Schönegg R,
Novotny H, Grilli B, Herzog M, Barascud AD, Zlobec I, Cathomas G,
Terracciano L, Feichter G and Bubendorf L: HER2 gene status in
primary breast cancers and matched distant metastases. Breast
Cancer Res. 9:R312007. View
Article : Google Scholar : PubMed/NCBI
|
|
28
|
Untch M, Muscholl M, Tjulandin S, Jonat W,
Meerpohl HG, Lichinitser M, Manikhas AG, Coumbos A, Kreienberg R,
du Bois A, Harbeck N, Jackisch C, Müller V, Pauschinger M, Thomssen
C, Lehle M, Catalani O and Lück HJ: First-line trastuzumab plus
epirubicin and cyclophosphamide therapy in patients with human
epidermal growth factor receptor 2-positive metastatic breast
cancer: cardiac safety and efficacy data from the Herceptin,
Cyclophosphamide, and Epirubicin (HERCULES) trial. J Clin Oncol.
28:1473–1480. 2010.
|
|
29
|
Spector NL and Blackwell KL: Understanding
the mechanisms behind trastuzumab therapy for human epidermal
growth factor receptor 2-positive breast cancer. J Clin Oncol.
27:5838–5847. 2009. View Article : Google Scholar : PubMed/NCBI
|
